Modified alginates for anti-fibrotic materials and applications
Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
1. A macrodevice coated with a modified alginate polymer, wherein the macrodevice comprises a cell that produces a therapeutically effective substance and the modified alginate polymer is selected from the group consisting of alginate-O—R 1 , alginate-S—R 1 , and alginate-N—R 1 , wherein
—N— is covalently bound to R 2 , and R 2 is one of the following: hydrogen, alkyl, or substituted alkyl,
R 1 has the structure
-A-B(—C) δ , Formula XVI
A is
wherein R 24 in A is —(CR 25 R 25 ) p —, p is an integer from 0 to 5, each R 25 is hydrogen, each R e is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic, y is an integer from 0 to 11, R 18 , R 19 , R 20 , R 21 , R 22 , and R 23 are independently C or N, wherein the bonds between adjacent R 18 to R 23 are double or single according to valency, and wherein R 18 to R 23 are bound to none, one, or two hydrogens according to valency, or
wherein R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 in A are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, alkoxy, substituted alkoxy, aroxy, substituted aroxy, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, substituted heterocyclic, poly(ethylene glycol), or poly(lactic-co-glycolic acid), k is an integer from 0 to 20, each X d is independently absent, O, or S, and R c is B,
B is
wherein R 8 and R 9 are independently hydrogen or C,
C is
wherein R 24 in C is —(CR 25 R 25 ) p — or —(CR 25 R 19 ) p —X b —(CR 25 R 25 ) q —, wherein p and q are independently integers from 0 to 5, X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 4 , each R 25 is hydrogen, R 4 is alkyl or substituted alkyl, R e are independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic, z is an integer from 0 to 11, wherein R 18 , R 19 , R 20 , R 21 , R 22 , and R 23 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 18 to R 23 are double or single according to valency, and wherein R 18 to R 23 are bound to none, one, or two hydrogens according to valency, and
wherein δ is 1.
2. The macrodevice of claim 1 , wherein the cell comprises a genetically engineered cell.
3. The macrodevice of claim 1 , wherein the cell comprises a retinal epithelial cell.
4. The macrodevice of claim 1 , wherein the therapeutically effective substance is provided in a sufficient amount to treat a disorder selected from diabetes, hemophilia, lysosomal storage disorders, neurodegenerative disorders, chronic inflammatory autoimmune diseases, cancer, liver diseases, impaired fracture, delayed union fraction, osteonecrosis, osteoporosis, disorders of amino acid metabolism, disorders of organic acid metabolism, disorders of fatty acid metabolism, disorders of purine metabolism, disorders of pyrimidine metabolism, disorders of urea formation, and disorders of peroxisomal metabolism.
5. The macrodevice of claim 4 , wherein the disorder is selected from diabetes, hemophilia, or a lysosomal storage disorder.
6. The macrodevice of claim 1 , wherein the therapeutically effective substance comprises protein.
7. The macrodevice of claim 1 , wherein the therapeutically effective substance is a peptide or protein comprising a hormone, growth factor, enzyme, antibody, or cytokine.
8. The macrodevice of claim 1 , wherein
R 1 is, independently in one or more sites of chemical modification,
R 4 , and R 5 , are, independently, hydrogen, —CH 2 —OH, or C,
wherein, C is methyl, —COCH 3 , —CH 2 —N(CH 2 —CH 3 ) 2 ,
9. The macrodevice of claim 1 , wherein —NR 2 —R 1 comprises:
10. A method of providing a therapeutically effective substance to a subject comprising implanting in the subject a macrodevice coated with a modified alginate polymer, wherein the macrodevice comprises a cell that produces a therapeutically effective substance and the modified alginate polymer is selected from the group consisting of alginate-O—R 1 , alginate-S—R 1 , and alginate-N—R 1 , wherein
—N— is covalently bound to R 2 , and R 2 is one of the following: hydrogen, alkyl, or substituted alkyl,
R 1 has the structure
-A-B(—C) δ , Formula XVI
A is
wherein R 24 in A is —(CR 25 R 25 ) p —, p is an integer from 0 to 5, each R 25 is hydrogen, each R e is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic, y is an integer from 0 to 11, R 18 , R 19 , R 20 , R 21 , R 22 , and R 23 are independently C or N, wherein the bonds between adjacent R 18 to R 23 are double or single according to valency, and wherein R 18 to R 23 are bound to none, one, or two hydrogens according to valency, or
wherein R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 in A are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, alkoxy, substituted alkoxy, aroxy, substituted aroxy, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, substituted heterocyclic, poly(ethylene glycol), or poly(lactic-co-glycolic acid), k is an integer from 0 to 20, each X d is independently absent, O, or S, and R c is B,
B is
wherein R 8 and R 9 are independently hydrogen or C,
C is
wherein R 24 in C is —(CR 25 R 25 ) p — or —(CR 25 R 19 ) p —X b —(CR 25 R 25 ) q —, wherein p and q are independently integers from 0 to 5, X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 4 , each R 25 is hydrogen, R 4 is alkyl or substituted alkyl, R e are independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic, z is an integer from 0 to 11, wherein R 18 , R 19 , R 20 , R 21 , R 22 , and R 23 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 18 to R 23 are double or single according to valency, and wherein R 18 to R 23 are bound to none, one, or two hydrogens according to valency, and
wherein δ is 1.
11. The method of claim 10 , wherein the cell comprises a genetically engineered cell.
12. The method of claim 10 , wherein the cell comprises a retinal epithelial cell.
13. The method of claim 10 , wherein the disorder is selected from diabetes, hemophilia, or a lysosomal storage disorder.
14. The method of claim 10 , wherein the therapeutically effective substance comprises a protein.
15. The method of claim 10 , wherein the therapeutically effective substance is selected from the group consisting of hormones, growth factors, enzymes, antibodies, and cytokines.
16. The method of claim 10 , wherein
R 1 is, independently in one or more sites of chemical modification,
R 4 , and R 5 , are, independently, hydrogen, —CH 2 —OH, or C,
wherein, C is methyl, —COCH 3 , —CH 2 —N(CH 2 —CH 3 ) 2 ,
17. The method of claim 10 , wherein —NR 2 —R 1 comprises:
18. A macrodevice coated with a modified alginate polymer, wherein the macrodevice comprises a cell that produces a therapeutically effective substance and the modified alginate polymer is selected from the group consisting of alginate-O—R 1 , alginate-S—R 1 , and alginate-N—R 1 , wherein
—N— is covalently bound to R 2 , and R 2 is one of the following: hydrogen, alkyl, or substituted alkyl,
R 1 is, independently in one or more sites of chemical modification,
wherein the modified alginate polymer is singularly modified.
19. A method of providing a therapeutically effective substance to a subject comprising implanting in the subject a macrodevice coated with a modified alginate polymer, wherein the macrodevice comprises a cell that produces the therapeutically effective substance and the modified alginate polymer is selected from the group consisting of alginate-O—R 1 , alginate-S—R 1 , and alginate-N—R 1 , wherein
—N— is covalently bound to R 2 , and R 2 is one of the following: hydrogen, alkyl, or substituted alkyl,
R 1 is, independently in one or more sites of chemical modification,
wherein the modified alginate polymer is singularly modified.
20. The macrodevice of claim 1 , wherein in A:
(i) R 18 , R 19 , R 20 , R 21 , R 22 , and R 23 are C, or
(ii) one, two, three, four, or five of R 18 , R 19 , R 20 , R 21 , R 22 , and R 23 are N and the others are C.
21. The macrodevice of claim 20 , wherein R 18 , R 19 , R 20 , R 21 , R 22 , and R 23 are C.
22. The macrodevice of claim 21 , wherein R 18 , R 19 , R 20 , R 21 , R 22 , and R 23 form a substituted phenyl group.
23. The macrodevice of claim 1 , wherein A is
X d is O,
R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are hydrogen, and
k is 3.